Journal
ENDOCRINOLOGY AND METABOLISM
Volume 34, Issue 1, Pages 1-10Publisher
KOREAN ENDOCRINE SOC
DOI: 10.3803/EnM.2019.34.1.1
Keywords
Genome; Transcriptome; Thyroid cancer, papillary; Thyroid cancer, follicular; High-throughput nucleotide sequencing
Categories
Funding
- Basic Science Research Program through the National Research Foundation of Korea - Ministry of Science, ICT & Future Planning [NRF-2016R1A2B4012417]
Ask authors/readers for more resources
Since the release of The Cancer Genome Atlas study of papillary thyroid carcinoma (PTC) in 2014, additional genomic studies of differentiated thyroid carcinoma (DTC) using massively-parallel sequencing (MPS) have been published. Recent advances in MPS technology have started to provide important insights into the molecular pathogenesis of DTC. In the genomic landscape, the most recurrently altered genes in DTC, which has a low mutational burden relative to other cancers, are BRAF, RAS, and fusion genes. Some novel driver candidates also have been identified. The frequency of these genomic alterations varies across the subtypes of DTC (classical PTC, follicular variant of PTC, and follicular thyroid carcinoma). Telomerase reverse transcriptase (TERT) promoter mutations are the alteration that makes the most important contribution to the progression of DTC. In the transcriptomic landscape, DTC can be classified according to its gene expression profile, and each subtype has a distinct mutational profile, intracellular signaling output, and clinicopathological characteristics. Herein, we review the results of genomic studies using MPS technology, and describe the types and frequencies of genomic alterations according to histological classifications of DTC and the characteristics and significance of the gene expression signatures of DTC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available